Incyte (INCY) Stock Could Be 31% Stretched Following KRAS Data Buzz

Incyte stock has delivered a strong 92.3% gain over the past three years, yet current valuation checks suggest investors may be paying a premium to the intrinsic value estimate while traditional multiples look more in line with peers. The result is a stock that no longer looks obviously cheap, even after a solid multi year run.

• Incyte has returned 92.3% over three years, which puts more pressure on today’s valuation to be supported by future cash flows rather than past share price gains.
• Upcoming data for Incyte’s KRAS G12D inhibitor at ESMO can inform expectations for future oncology cash flows. However, there is a risk that competitors such as Revolution Medicines execute more quickly in the same treatment area and limit potential upside.
• The Discounted Cash Flow (DCF) intrinsic value estimate sits about 31% below the current share price, while the broader checks including earnings multiples and other ratios point to an approximately fair valuation. This mixed picture does not present a clear bargain or a clear overvaluation and supports a mixed value score that rates Incyte at 3 on this framework.

The stock’s next move may depend on whether investors ultimately place more weight on the intrinsic value estimate, which indicates a premium, or on the market multiples, which suggest Incyte is closer to fairly priced.

Compare Incyte’s mixed valuation signals with other stocks that pair strong recent returns with more straightforward pricing using the hand picked 45 high quality undervalued stocks

Is Incyte Getting Expensive on Cash Flow?

The Discounted Cash Flow (DCF) model values Incyte by projecting the cash it could return to shareholders and then discounting those cash flows back to today. Incyte generated about $1.89b in free cash flow over the last twelve months, and the model assumes these cash flows soften from current levels rather than continue at their recent size.

On these assumptions, the DCF model points to an intrinsic value of about $94.93 per share. This sits about 31.0% below the current share price, so on this framework the stock screens as overvalued. The current debate around KRAS opportunities after Revolution Medicines won approval for Rasonque may help explain why the market price is running ahead of what the cash flow model supports for Incyte.

On the DCF numbers alone, Incyte stock currently looks overvalued relative to its modeled cash flow stream.

Our Discounted Cash Flow (DCF) analysis suggests Incyte may be overvalued by 31.0%. Discover 45 high quality undervalued stocks or create your own screener to find better value opportunities.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Incyte.

Does Incyte Look Fairly Valued on Earnings?

The P/E multiple suits Incyte because the company reports positive earnings that give you a clear anchor for what you pay per dollar of profit. On this basis, Incyte currently trades at about 15.6x earnings. That is lower than the broader biotech industry average of roughly 16.9x and also below the peer group average near 23.4x.

A tailored fair P/E ratio for Incyte is around 16.0x when factoring in its size, margins and risk profile. That is close to where the stock trades today, which means the current market price is broadly in line with what this framework suggests despite the recent excitement around KRAS data and competing products.

Overall, Incyte appears roughly fairly valued based on its P/E multiple.

See what the numbers say about this price — find out in our valuation breakdown.

The Incyte Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where this valuation puzzle for Incyte leaves off by spelling out which assumptions on growth, margins and earnings would need to hold for the stock to be worth materially more or less than today’s price, and they sit on the company’s Community page. Each Narrative treats Incyte’s fair value as a thesis about the business that you can revisit over time, rather than a one off snapshot.

The community split on Incyte is wide, with one side focused on a stronger post Jakafi portfolio and the other fixated on concentration and pricing risk.

Bull case: roughly fairly valued

"Strengthened and diversified product portfolio momentum (with Jakafi, Opzelura, Niktimvo, Monjuvi, and Zynyz all delivering robust growth) alongside an active business development pipeline increases resilience against biosimilar/generic threats and potentially derisks near/mid-term revenue..."

Read the full Bull Case to see why Incyte could be undervalued

Bear case: 34% overvalued

"The company's heavy reliance on Jakafi exposes it to severe concentration risk, with biosimilar competition and patent expiry after 2028 expected to cause a sharp decline in sales and profitability, as diversification efforts into new products may not ramp fast enough to offset this erosion..."

Read the full Bear Case to see why Incyte could be overvalued

Do you think there's more to the story for Incyte? Head over to our Community to see what others are saying!

The Bottom Line

For Incyte, the Discounted Cash Flow (DCF) view flags the stock as overvalued, while the earnings multiple view points closer to about right. That gap comes down to cash flow timing and investment needs on one side and what the market is willing to pay for earnings and future growth on the other. The crux for investors is whether Incyte can translate its pipeline and post Jakafi portfolio into cash flows that justify today’s price, or whether current expectations already bake in most of that upside.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com